Effect of screening for Type2 diabetes on population-level self-rated health outcomes and measures of cardiovascular risk: 13-year follow-up of the Ely cohort

Diabetic Medicine

Volumn 29, Issue 7, 2012, Pages 886-892

  Rahman, M ^a,b   Simmons, R K ^c   Hennings, S H ^c   Wareham, N J ^c   Griffin, S J ^c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b NORTHWICK PARK HOSPITAL   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Diabetes; Ely; Mortality; Population; Screening

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; GENERAL PRACTICE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRESCRIPTION; RANDOMIZATION; SAMPLING; SCREENING; SELF REPORT; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; DIABETIC ANGIOPATHY; EARLY DIAGNOSIS; GLUCOSE TOLERANCE TEST; HEALTH CARE DELIVERY; HEALTH STATUS; MASS SCREENING; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICS; TIME; UNITED KINGDOM;

ADULT; AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; DELIVERY OF HEALTH CARE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; EARLY DIAGNOSIS; FEMALE; FOLLOW-UP STUDIES; GLUCOSE TOLERANCE TEST; GREAT BRITAIN; HEALTH STATUS; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RISK FACTORS; TIME FACTORS;

EID: 84862661244     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2012.03570.x     Document Type: Article

References (34)

1. Simmons RK, Echouffo-Tcheugui JB, Griffin SJ. Screening for type2 diabetes: an update of the evidence. Diabetes Obes Metab 2010; 12: 838-844.
2. Department of Health. Putting Prevention First Vascular Checks: Risk Assessment and Management. London: Department of Health, 2008.
3. Wareham NJ, Griffin SJ. Should we screen for type2 diabetes? Evaluation against National Screening Committee criteria. Br Med J 2001; 322: 986-988.
4. Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandbaek A et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 2011; 378: 156-167.
5. Kahn R, Alperin P, Eddy D, Borch-Johnsen K, Buse J, Feigelman J et al. Age at initiation and frequency of screening to detect type2 diabetes: a cost-effectiveness analysis. Lancet 2010; 375: 1365-1374.
6. Simmons RK, Rahman M, Jakes RW, Yuyun MF, Niggebrugge AR, Hennings SH et al. Effect of population screening for type2 diabetes on mortality: long-term follow-up of the Ely cohort. Diabetologia 2011; 54: 312-319.
7. Bankhead CR, Brett J, Bukach C, Webster P, Stewart-Brown S, Munafo M et al. The impact of screening on future health-promoting behaviours and health beliefs: a systematic review. Health Technol Assess 2003; 7: 1-92.
8. Strecher VJ, Kreuter MW. The psychosocial and behavourial effects of health risk appraisals. In: Croyle RT, ed. Psychosocial Effects of Screening for Disease Prevention and Detection New York: Oxford University Press, 1995.
9. Stewart-Brown S, Farmer A. Screening could seriously damage your health. Br Med J 1997; 314: 533-534.
10. Tymstra T, Bieleman B. The psychosocial impact of mass screening for cardiovascular risk factors. Fam Pract 1987; 4: 287-290.
11. Echouffo-Tcheugui JB, Simmons RK, Williams KM, Barling RS, Prevost AT, Kinmonth AL et al. The ADDITION-Cambridge trial protocol: a cluster-randomised controlled trial of screening for type2 diabetes and intensive treatment for screen-detected patients. BMC Public Health 2009; 9: 136.
12. Eborall HC, Griffin SJ, Prevost AT, Kinmonth AL, French DP, Sutton S. Psychological impact of screening for type2 diabetes: controlled trial and comparative study embedded in the ADDITION (Cambridge) randomised controlled trial. Br Med J 2007; 335: 486.
13. Paddison CA, Eborall HC, Sutton S, French DP, Vasconcelos J, Prevost AT et al. Are people with negative diabetes screening tests falsely reassured? Parallel group cohort study embedded in the ADDITION (Cambridge) randomised controlled trial. Br Med J 2009; 339: b4535.
14. DeSalvo KB, Bloser N, Reynolds K, He J, Muntner P. Mortality prediction with a single general self-rated health question. A meta-analysis. J Gen Intern Med 2006; 21: 267-275.
15. Black WC, Welch HG. Screening for disease. Am J Roentgenol 1997; 168: 3-11.
16. Edelman D, Olsen MK, Dudley TK, Harris AC, Oddone EZ. Impact of diabetes screening on quality of life. Diabetes Care 2002; 25: 1022-1026.
17. Adriaanse MC, Snoek FJ, Dekker JM, Spijkerman AM, Nijpels G, Twisk JW et al. No substantial psychological impact of the diagnosis of Type2 diabetes following targeted population screening: The Hoorn Screening Study. Diabet Med 2004; 21: 992-998.
18. Adriaanse MC, Dekker JM, Spijkerman AM, Twisk JW, Nijpels G, van der Ploeg HM et al. Health-related quality of life in the first year following diagnosis of Type2 diabetes: newly diagnosed patients in general practice compared with screening-detected patients. The Hoorn Screening Study. Diabet Med 2004; 21: 1075-1081.
19. Williams DR, Wareham NJ, Brown DC, Byrne CD, Clark PM, Cox BD et al. Undiagnosed glucose intolerance in the community: the Isle of Ely Diabetes Project. Diabet Med 1995; 12: 30-35.
20. Townsend P, Phillimore P., Beattie A. Health and Deprivation: Inequality and the North. London: Croom Helm, 2004.
21. Rose G, McCartney P, Reid DD. Self-administration of a questionnaire on chest pain and intermittent claudication. Brit J Prev Soc Med 1977; 31: 42-48.
22. Rose GA. Ischemic heart disease. Chest pain questionnaire. Milbank Mem Fund Q 1965; 43: 32-39.
23. Ware JE SK, Kosinski M, Gandek B. SF-36 Health Survey. Manual and Interpretation Guide. Boston, MA: New England Medical Centre, The Health Institute, 1993.
24. EuroQol. EuroQol-a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990; 16: 199-208.
25. Rahman M, Simmons RK, Hennings SH, Wareham NJ, Griffin SJ. How much does screening bring forward the diagnosis of diabetes and reduce complications? 12-year follow-up of the Ely cohort. Diabetologia 2012; 55: 1651-1659.
26. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a UK national questionnaire survey. Br Med J 1998; 316: 736-741.
27. Marteau TM, Kinmonth AL, Thompson S, Pyke S. The psychological impact of cardiovascular screening and intervention in primary care: a problem of false reassurance? British Family Heart Study Group. Br J Gen Pract 1996; 46: 577-582.
28. Diabetes UK. Early Identification of People with Type2 Diabetes. Position Statement. Available at Last accessed 13 December 2011.
29. Department of Health. Putting Prevention First - Vascular Checks: Risk Assessment and Management. London: Department of Health, 2008.
30. Doran T, Fullwood C, Gravelle H, Reeves D, Kontopantelis E, Hiroeh U et al. Pay-for-performance programs in family practices in the UK. N Engl J Med 2006; 355: 375-384.
31. OXCHECK. Effectiveness of health checks conducted by nurses in primary care: final results of the OXCHECK study. Imperial Cancer Research Fund OXCHECK Study Group. Br Med J 1995; 310: 1099-1104.
32. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009; 32: 1327-1334.
33. 1c with cardiovascular disease and mortality in adults: the European Prospective Investigation into Cancer in Norfolk. Ann Intern Med 2004; 141: 413-420.
34. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993; 118: 622-629.